

Paul P Dobesh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3673436/publications.pdf>

Version: 2024-02-01

78
papers

2,233
citations

331538

21
h-index

223716

46
g-index

79
all docs

79
docs citations

79
times ranked

3416
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	3.8	515
2	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3042-3067.	1.2	285
3	Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety. <i>Pharmacotherapy</i> , 2014, 34, 1077-1090.	1.2	161
4	Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 165-186.	1.0	156
5	Economic Burden of Venous Thromboembolism in Hospitalized Patients. <i>Pharmacotherapy</i> , 2009, 29, 943-953.	1.2	113
6	Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor. <i>Pharmacotherapy</i> , 2009, 29, 1089-1102.	1.2	78
7	Reduction in Mortality Associated with Statin Therapy in Patients with Severe Sepsis. <i>Pharmacotherapy</i> , 2009, 29, 621-630.	1.2	77
8	Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. <i>Pharmacotherapy</i> , 2020, 40, 1130-1151.	1.2	63
9	Effect of a Clinical Pharmacy Education Program on Improvement in the Quantity and Quality of Venous Thromboembolism Prophylaxis for Medically Ill Patients. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, 755-762.	2.2	57
10	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141.	1.8	55
11	Adherence and dosing frequency of common medications for cardiovascular patients. <i>American Journal of Managed Care</i> , 2012, 18, 139-46.	0.8	54
12	Management of Periprocedural Anticoagulation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 217-226.	1.2	45
13	Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2017, 130, 1015-1023.	0.6	38
14	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. <i>Drugs</i> , 2015, 75, 1627-1644.	4.9	37
15	Statins role in the prevention and treatment of sepsis. <i>Pharmacological Research</i> , 2014, 88, 31-40.	3.1	29
16	Drug-Eluting Stents: A Mechanical and Pharmacologic Approach to Coronary Artery Disease. <i>Pharmacotherapy</i> , 2004, 24, 1554-1577.	1.2	28
17	Prevention of Venous Thromboembolism in Acute Medical Illness. <i>Pharmacotherapy</i> , 2002, 22, 1564-1578.	1.2	25
18	Clopidogrel Response Variability. <i>Journal of Pharmacy Practice</i> , 2016, 29, 26-34.	0.5	24

#	ARTICLE	IF	CITATIONS
19	Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. <i>Future Cardiology</i> , 2021, 17, 127-135.	0.5	24
20	New Oral Anticoagulants for the Treatment of Venous Thromboembolism: Understanding Differences and Similarities. <i>Drugs</i> , 2014, 74, 2015-2032.	4.9	21
21	Management of Venous Thromboembolism. <i>Annals of Pharmacotherapy</i> , 2016, 50, 486-501.	0.9	21
22	Clinically important interaction between statin drugs and Clostridium difficile toxin?. <i>Medical Hypotheses</i> , 2009, 73, 1045-1047.	0.8	20
23	Key Articles and Guidelines for the Prevention of Venous Thromboembolism. <i>Pharmacotherapy</i> , 2009, 29, 410-458.	1.2	19
24	Role of the Pharmacist in Achieving Performance Measures to Improve the Prevention and Treatment of Venous Thromboembolism. <i>Pharmacotherapy</i> , 2013, 33, 650-664.	1.2	18
25	Managing hypertension in patients with type 2 diabetes mellitus. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1140-1149.	0.5	17
26	Critical Pathways: The Role of Pharmacy Today and Tomorrow. <i>Pharmacotherapy</i> , 2006, 26, 1358-1368.	1.2	16
27	Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. <i>American Heart Journal</i> , 2014, 167, 413-418.	1.2	13
28	Ranolazine: A New Option in the Management of Chronic Stable Angina. <i>Pharmacotherapy</i> , 2007, 27, 1659-1676.	1.2	12
29	Key Articles and Guidelines in the Management of Acute Coronary Syndrome and in Percutaneous Coronary Intervention: 2012 Update. <i>Pharmacotherapy</i> , 2012, 32, e348-86.	1.2	12
30	Traditional Management of Chronic Stable Angina. <i>Pharmacotherapy</i> , 2007, 27, 1677-1692.	1.2	11
31	Key Articles and Guidelines in the Treatment of Venous Thromboembolism. <i>Pharmacotherapy</i> , 2009, 29, 1385-1385.	1.2	11
32	Pharmacologic Therapy for Intermittent Claudication. <i>Pharmacotherapy</i> , 2009, 29, 526-553.	1.2	10
33	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients. <i>Pharmacotherapy</i> , 2018, 38, 597-609.	1.2	10
34	Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1558-1571.	0.9	9
35	Improving the use of anticoagulant therapies in acutely ill medical patients. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, S5-S12.	0.5	9
36	Statins in Sepsis. <i>Journal of Pharmacy Practice</i> , 2010, 23, 38-49.	0.5	9

#	ARTICLE	IF	CITATIONS
37	Antidotes for reversal of direct oral anticoagulants. , 2019, 204, 107405.		9
38	Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor. Current Pharmaceutical Design, 2016, 22, 1918-1932.	0.9	8
39	Key Articles and Guidelines Relative to Treatment of Patients with Acute Coronary Syndromes. Pharmacotherapy, 2004, 24, 105-144.	1.2	7
40	Evidence for Extended Prophylaxis in the Setting of Orthopedic Surgery. Pharmacotherapy, 2004, 24, 73S-81S.	1.2	7
41	Clopidogrel versus Prasugrel: Times Are Changing, but Not for Everyone. Pharmacotherapy, 2009, 29, 1393-1396.	1.2	7
42	Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism. American Journal of Medicine, 2017, 130, 1137-1143.	0.6	7
43	Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor. Journal of Cardiovascular Pharmacology, 2022, 79, 161-167.	0.8	6
44	Novel concepts: Emerging data and the role of extended prophylaxis following hip fracture surgery. American Journal of Health-System Pharmacy, 2003, 60, S15-S19.	0.5	5
45	Unfractionated Heparin Dosing Nomograms: Road Maps to Where?. Pharmacotherapy, 2004, 24, 142S-145S.	1.2	5
46	Key Articles and Guidelines in the Management of Acute Coronary Syndromes and in Percutaneous Coronary Intervention: 2007 Update. Pharmacotherapy, 2007, 27, 1722-1758.	1.2	5
47	Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. American Journal of Health-System Pharmacy, 2008, 65, S22-S28.	0.5	5
48	Economic Implications of Inadequate Treatment of Venous Thromboembolism and Potential Solutions. Journal of Pharmacy Practice, 2014, 27, 178-186.	0.5	5
49	Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?. Journal of Atrial Fibrillation, 2016, 9, 1481.	0.5	5
50	Key Articles and Guidelines in the Management of Peripheral Arterial Disease. Pharmacotherapy, 2011, 31, 922-922.	1.2	4
51	The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. Cardiovascular Drugs and Therapy, 2017, 31, 433-444.	1.3	4
52	Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. Clinical Therapeutics, 2020, 42, 2084-2097.	1.1	4
53	Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?. Current Emergency and Hospital Medicine Reports, 2013, 1, 208-216.	0.6	3
54	Novel Direct-Acting Anticoagulants for Risk Reduction in ACS. Journal of Pharmacy Practice, 2013, 26, 358-366.	0.5	3

#	ARTICLE	IF	CITATIONS
55	Cangrelor for treatment during percutaneous coronary intervention. <i>Future Cardiology</i> , 2014, 10, 201-213.	0.5	3
56	Key Articles and Guidelines in the Management of Hypertension. <i>Journal of Pharmacy Practice</i> , 2015, 28, 146-161.	0.5	3
57	Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis. <i>American Journal of Medicine</i> , 2019, 132, 307-311.	0.6	3
58	Administration of Glycoprotein IIb/IIIa Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction. <i>Pharmacotherapy</i> , 2002, 22, 864-888.	1.2	2
59	Economics of Unfractionated Heparin: Beyond Acquisition Cost. <i>Pharmacotherapy</i> , 2004, 24, 161S-164S.	1.2	2
60	Ximelagatran: Pharmacology, Pharmacokinetics, and Pharmacodynamics. <i>Pharmacotherapy</i> , 2004, 24, 169S-178S.	1.2	2
61	Stable Angina. <i>Journal of Managed Care Pharmacy</i> , 2006, 12, S4-S9.	2.2	2
62	Potential unrecognised costs of clopidogrel pretreatment in acute coronary syndrome. <i>Journal of Medical Economics</i> , 2009, 12, 325-330.	1.0	2
63	Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures. <i>Cardiology in Review</i> , 2018, 26, 245-254.	0.6	2
64	Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. <i>Pharmacotherapy</i> , 2019, 39, 94-108.	1.2	2
65	Pharmacology of Oral Anticoagulants. , 2019, , 11-34.		2
66	Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism: Use in Patients with Advanced Renal Impairment, Obesity, or Other Weight-Related Special Populations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 233-249.	0.8	2
67	Knowledge of Hospital Acquisition Costs of Antibiotics among Physicians in a Community Hospital. <i>Hospital Pharmacy</i> , 2002, 37, 833-839.	0.4	1
68	Anticoagulation in the Management of Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of Pharmacy Practice</i> , 2010, 23, 324-334.	0.5	1
69	Are Hospitals Following Guidelines for VTE Prevention? the Venous Thromboembolism Study to Assess the Rate of Thromboprophylaxis. <i>Blood</i> , 2008, 112, 1286-1286.	0.6	1
70	The Impact of Eliminating Backward Navigation on Computerized Examination Scores and Completion Time. <i>American Journal of Pharmaceutical Education</i> , 2020, 84, ajpe8034.	0.7	1
71	Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis. <i>American Journal of Managed Care</i> , 2018, 24, S468-S474.	0.8	1
72	Outcomes with Changes in Prescribing of Glycoprotein IIb/IIIa Inhibitors in PCI. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1375-1380.	0.9	0

#	ARTICLE	IF	CITATIONS
73	Commentary. Evidence-based Cardiovascular Medicine, 2005, 9, 182-183.	0.0	0
74	Anticoagulation in the Management of ST-Segment Elevation Myocardial Infarction. Journal of Pharmacy Practice, 2010, 23, 335-343.	0.5	0
75	When the Simulation Becomes Real. American Journal of Pharmaceutical Education, 2021, , 8552.	0.7	0
76	Bias in <i>AJHP</i> supplements. American Journal of Health-System Pharmacy, 2008, 65, 2329-2330.	0.5	0
77	The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients. American Journal of Managed Care, 2018, 24, S475-S482.	0.8	0
78	Best practices for implementing venous thromboembolism prophylaxis across the continuum of care. American Journal of Managed Care, 2018, 24, S483-S488.	0.8	0